<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142970</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-106</org_study_id>
    <nct_id>NCT04142970</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions</brief_title>
  <official_title>A Clinical Study Comparatively Evaluating the Pharmacokinetics, Pharmacodynamics and Safety of Intravenous Administration of HSK3486 Injectable Emulsion in Patients With Chronic Renal Impairment and Subjects With Normal Renal Functions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Study Comparatively Evaluating the Pharmacokinetics, Pharmacodynamics and Safety
      of Intravenous Administration of HSK3486 Injectable Emulsion in Patients with Chronic Renal
      Impairment and Subjects with Normal Renal Functions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, non-randomized, parallel-controlled Phase I clinical
      study carried out in subjects with varying degrees (mild or moderate) of renal impairment,
      and age-, weight-, and gender-matched subjects with normal renal functions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak concentration (Cmax)</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>Cmax（a measure of the body's exposure to HSK3486）will be compared between normal renal function patients and mild or moderate chronic renal impairment patients .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve（AUC）</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>AUC（a measure of the body's exposure to HSK3486）will be compared between normal renal function patients and mild or moderate chronic renal impairment patients .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MOAA/S(modified observer's assessment of alert /sedation)</measure>
    <time_frame>-5 minutes before administration until 1 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectral index(BIS)</measure>
    <time_frame>-5 minutes before administration until 1 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>time to peak observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure（systolic, diastolic and mean arterial pressure）</measure>
    <time_frame>from the screening to 3 days post-dose</time_frame>
    <description>safety endpoits</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mild renal impairment (eGFR: 60-89 mL/min/1.73 m^2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderate renal impairment (eGFR: 30-59 mL/min/1.73 m^2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with normal renal functions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with normal renal functions (eGFR: ≥ 90 mL/min/1.73 m^2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.</description>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_label>Subjects with normal renal functions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject Inclusion Criteria (Must Meet All of the Following Criteria):

        Inclusion Criteria:

          1. Males or females with full capacity for civil conduct, aged ≥ 18 and &lt; 65 years old;

          2. Weighing ≥ 45 kg, and with a body mass index (BMI) of ≥ 18 and ≤ 28 kg/ m^2(BMI =
             weight (kg)/height2 ( m^2));

          3. For matched subjects with normal renal functions: physical examination, laboratory
             tests (blood routine, blood biochemistry, urine routine, urinary albumin/creatinine
             ratio, creatine kinase (CK) and coagulation function), and 12-lead ECG, etc. should be
             normal or abnormal without clinical significance as determined by the investigator;

          4. No potential difficult airway (modified Mallampati score of Grade I to II);

          5. For matched subjects with normal renal functions: no history of major organ primary
             diseases, such as liver, kidneys, digestive tract, blood, and metabolic diseases; no
             history of malignant hyperthermia and other genetic conditions; no history of
             mental/neurological diseases; no history of epilepsy; no contraindications for deep
             sedation/general anesthesia; no clinically significant history of anesthesia
             accidents;

          6. Subjects must understand the procedures and methods of this study, and be willing to
             signing the informed consent form and to complete the trial in strict accordance with
             clinical trial protocol;

             Patients with Renal Impairment Must Also Meet the Following Criteria:

          7. The estimated glomerular filtration rate (eGFR) of the subjects in corresponding
             groups meets the criteria for mild to moderate renal impairment in the staging of
             renal functions, i.e., mild renal impairment: 60-89 mL/min/1.73 m^2; moderate renal
             impairment: 30-59 mL/min/1.73 m^2; subjects with normal renal functions: ≥ 90
             mL/min/1.73 m^2;

          8. For subjects with renal impairment, their laboratory test results (coagulation
             function, blood routine, urinary albumin/creatinine ratio, creatine kinase (CK), blood
             biochemistry, and urine routine) should be judged by the investigators as clinically
             stable and consistent with the severity of their renal impairment. In addition, their
             albumin should be &gt; 35 g/L and hemoglobin should be &gt; 110 g/L;

        Exclusion Criteria( those who meet any one of the followings are ineligible):

          1. Known sensitivity to excipients in HSK3486 injectable emulsion (soybean oil, glycerin,
             triglyceride, egg lecithin, sodium oleate and sodium hydroxide); history of drug
             allergies (including other anesthetics);

          2. Received any one of the following medications or treatments prior to
             screening/enrollment:

             History of drug abuse or any signs of long-term use of benzodiazepines (such as
             insomnia, anxiety, spasms) within 3 months prior to screening; Participated in
             clinical trials involving any medications or medical devices within 3 months prior to
             screening, or subjects who have participated in 3 or more drug clinical trials within
             the past year; Serious infection, trauma, or major surgery within 4 weeks before
             screening; or acute disease with clinical significance (determined by the
             investigators) within 2 weeks before screening, including GI diseases or infections
             (such as respiratory tract or CNS infections); In receipt of propofol, other
             sedatives/anesthetics and/or opioid analgesics or compounds containing analgesics
             within 72 hrs prior to baseline; Used potent inhibitors of CYP enzyme within 7 days
             prior to enrollment, or used moderate/low potency inhibitors of CYP enzyme within 3
             days prior to enrollment;

          3. History or evidence of any one of the following diseases prior to
             screening/enrollment:

             History of cardiovascular diseases such as: uncontrolled hypertension [SBP ≥ 170 mmHg
             and/or DBP ≥ 105 without antihypertensive treatment, or SBP &gt; 160 mmHg and/or DBP &gt;
             100 mmHg despite antihypertensive treatment], postural hypotension, severe arrhythmia,
             heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within 6
             months before screening, history of tachycardia/bradycardia requiring medication,
             II-III degree atrioventricular block (excluding patients with pacemakers) or QTcF
             interval ≥ 450 ms (Fridericia's correction formula); Respiratory insufficiency,
             history of obstructive pulmonary disease, history of asthma, sleep apnea; history of
             failed tracheal intubation; history of bronchospasm requiring treatment within 3
             months prior to screening; acute respiratory infection, and with obvious symptoms such
             as fever, wheezing, nasal congestion or cough within 1 week prior to baseline; History
             of gastrointestinal diseases: History of gastrointestinal retention, moderate and
             above active bleeding (GUSTO bleeding classification), gastroesophageal reflux that
             may lead to aspiration; [Note: GUSTO bleeding classification is: heavy or
             life-threatening bleeding (intracranial hemorrhage or bleeding that causes hemodynamic
             compromise and requires intervention), moderate bleeding (requires blood transfusion
             but does not cause hemodynamic compromise), minor bleeding (does not meet the criteria
             for either severe or moderate bleeding)]; History of cerebrovascular diseases: history
             of craniocerebral injury, possible convulsions, intracranial hypertension, cerebral
             aneurysm, or cerebrovascular accident; History of mental illness: schizophrenia,
             mania, chronic use of antipsychotics, or cognitive impairment;

          4. Positive test for either HBsAg, HCV, HIV, or syphilis;

          5. History of alcohol abuse within 3 months prior to screening, alcohol abuse defined as
             average of &gt; 2 units of alcohol per day (1 unit = 360 mL beer or 45 mL liquor with 40%
             alcohol or 150 mL wine), or positive alcohol breath test results at baseline;

          6. Smoke more than 5 cigarettes per day and a total of more than 60 cigarettes within 3
             months prior to screening;

          7. Blood donation or blood loss ≥ 200 mL within 30 days prior to screening; plasma
             donation or plasma exchange within 7 days prior to screening;

          8. Subjects who have consumed any beverages or foods containing alcohol, grapefruit juice
             or methylxanthine (such as coffee, tea, cola, chocolate, and functional drinks),
             participated in strenuous physical activities and other factors that may affect drug
             absorption, distribution, metabolism, and excretion within 2 days prior to baseline;
             subjects who are unable to fast for 8 hrs before dose administration;

          9. Subjects expected to have surgery or hospitalization during the trial;

         10. Subjects unsuitable for arterial blood collection, such as subjects who have positive
             Allen's test results;

         11. Other than the disease diagnosed as renal impairment, patients with acute illnesses in
             any other organ, as well as those with chronic conditions that may affect the in vivo
             process of the investigational drug (e.g., chronic hepatitis, hepatic insufficiency,
             etc.);

         12. Patients with autoimmune nephropathy, obstructive nephropathy, history of kidney
             transplantation, and an ongoing dialysis treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shi-ping Ma, PhD</last_name>
    <phone>(021)50799069</phone>
    <email>masp@haisco.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kai Chen, PhD</last_name>
    <phone>(028)67258864</phone>
    <email>chenk@haisco.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>He Nan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang-suo Liu, PhD</last_name>
      <phone>0371-66295219</phone>
      <email>tianli_llzl@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Qin L, Ren L, Wan S, Liu G, Luo X, Liu Z, Li F, Yu Y, Liu J, Wei Y. Design, Synthesis, and Evaluation of Novel 2,6-Disubstituted Phenol Derivatives as General Anesthetics. J Med Chem. 2017 May 11;60(9):3606-3617. doi: 10.1021/acs.jmedchem.7b00254. Epub 2017 Apr 28.</citation>
    <PMID>28430430</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild renal impairment</keyword>
  <keyword>Moderate renal impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

